EP0025898B1 - Antibiotic c-15003 pnd-0 and production of antibiotic c-15003 pnd - Google Patents

Antibiotic c-15003 pnd-0 and production of antibiotic c-15003 pnd Download PDF

Info

Publication number
EP0025898B1
EP0025898B1 EP80105162A EP80105162A EP0025898B1 EP 0025898 B1 EP0025898 B1 EP 0025898B1 EP 80105162 A EP80105162 A EP 80105162A EP 80105162 A EP80105162 A EP 80105162A EP 0025898 B1 EP0025898 B1 EP 0025898B1
Authority
EP
European Patent Office
Prior art keywords
pnd
streptomyces
ifo
antibiotic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP80105162A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0025898A3 (en
EP0025898A2 (en
Inventor
Makoto Kida
Motowo Izawa
Kazuo Nakahama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to AT80105162T priority Critical patent/ATE3059T1/de
Publication of EP0025898A2 publication Critical patent/EP0025898A2/en
Publication of EP0025898A3 publication Critical patent/EP0025898A3/en
Application granted granted Critical
Publication of EP0025898B1 publication Critical patent/EP0025898B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/14—Chainia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia

Definitions

  • This invention relates to a method of producing Antibiotic C-15003 PND.
  • Antibiotic C-15003 PND compounds can be obtained by cultivating a microorganism, for example Nocardia sp. No. C-15003 [deposited at Fermentation Research Institute, Agency of Industrial Science and Technology, Japan under the number of FERM-P No. 3992, Institute for Fermentation, Osaka, Japan under the accession number of IFO 13726 and the American Type Culture Collection, U.S.A., under the number of ATCC 31281], in a culture medium and harvesting and purifying them from the fermentation broth. These substances have potent antitumor activity.
  • the present inventors explored microbiological methods for a transformation of maytansinoid compounds [e.g. the compounds described in Nature, London, 270, 721 (1977) and Tetrahedron 35, 1079 (1979)] into other compounds, and discovered that when a culture broth, inclusive of processed matters derived therefrom, of one of certain microorganisms is permitted to act upon maytansinoid compounds, the latter are converted to Antibiotic C-15003 PND and that when the resulting compounds are deacylated, the corresponding compounds having a hydroxyl group in 3-position are obtained.
  • the above finding was followed by further research which has resulted in the present invention.
  • This invention therefore, relates to:
  • the alkanoyl of not more than 5 carbon atoms as designated by R or R' may for example be formyl (-CHO), acetyl (-COCH 3 ), propionyl ( ⁇ COCH 2 CH 3 ), butyryl ( ⁇ COCH 2 CH 2 CH 3 ), isobutyryl or the like.
  • C-15003 PND or , simply, “PND” as used throughout this specification means all of the compounds of general formula (I), a mixture of two or more of such compounds or any one of the compounds.
  • R is hydrogen
  • C-15003 PND-0 or briefly as “PND-0”
  • the compound of formula (I) wherein R is ⁇ COCH 3 will be referred to as "C-15003 PND-1” or briefly as “PND-1”
  • the compound (I) wherein R is ⁇ COCH 2 CH 3 will be referred to as "C-15003 PND-2” or briefly as “PND-2”
  • the compound (I) wherein R is will be referred to as "C-15003 PND-3” or briefly as “PND-3”
  • the compound (I) wherein R is will be referred to as "C-15003 PND-4" or briefly as "PND-4".
  • P-2 maytansinol propionate
  • the compound (II) wherein R is will be referred to as "C-15003 P-3” or briefly as “P-3”
  • the compound (II) wherein R is -COCH 2 CH 2 CH 3 will be referred to as "C-15003 P-3'” or briefly as “P-3'”
  • the compound (II) wherein R is will be referred to as "C-15003 P-4" or briefly as "P-4".
  • C-15003 means all of the compounds of P-0, P-1, P-2, P-3, P-3' and P-4, a mixture of two or more of the compounds or any one of the compounds.
  • P ⁇ O, P-1, P-2, P-3, P-3' and P-4 can be obtained by cultivating a microorganism, for example Nocardia sp. No. C-15003 [FERM-P No. 3992; IFO 13726; ATCC 31281], in a culture medium and harvesting and purifying them from the fermentation broth [Nature vol. 270, p. 721 (1977), Tetrahedron 35, 1079 (1979), U.S. Patent No. 4,151,042, U.S. Patent No. 4,162,940.].
  • a microorganism for example Nocardia sp. No. C-15003 [FERM-P No. 3992; IFO 13726; ATCC 31281]
  • the strain ATCC 31281 is listed on "The American Type Culture Collection Catalogue of Strains I (Fourteenth Edition 1980)".
  • P-0 can also be obtained by deacylating P-3, P-3' and/or P-4 [Nature, vol. 270, p. 271 (1977), Tetrahedron 35, 1079, U.S. Patent No. 4,162,940.].
  • the compounds of general formula (II) wherein R is a substituent other than a hydrogen atom can be produced by reacting P-0 with an acid anhydride of general formula: [wherein R' is as defined above] derived from the corresponding carboxylic acid or with an acid halide of general formula: [wherein R' is as defined above; X is halogen] which is also derived from the corresponding carboxylic acid.
  • the halogen X may for example be chlorine, bromine or iodine.
  • a base may be mentioned tertiary amines such as triethylamine, tributylamine, pyridine, 4-dimethylaminopyridine, ⁇ , ⁇ - or y-picoline, 2,6-lutidine, dimethylaniline, diethylaniline, N-methylmorpholine, etc.
  • the above reaction may be conducted in an appropriate solvent which may for example be esters (e.g. ethyl acetate), ethers (e.g.
  • the microorganism employed in the method of this invention may be any organism belonging to one of the genera Streptomyces and Chainia which is capable of transforming the maytansinoid compound (II) into C-15003 PND (I), inclusive of variants and mutants thereof.
  • Streptomyces minutiscleroticus IFO 13361 ATCC 17757, 19346
  • Streptomyces roseiscleroticus IFO 13363 ATCC 17755
  • Streptomyces flaviscleroticus IFO 13357 ATCC 19347
  • Streptomyces olivaceiscleroticus IFO 13484 ATCC 15722
  • Streptomyces sclerotia/us IFO 12246 ATCC 15721
  • Chainia nigra IFO 13362 ATCC 17756
  • organisms of the genera Streptomyces and Chainia are highly variable in characteristics and can be mutated by artifical means such as X-ray, UV, gamma-ray or other irradiation, or with a mutagenic agent (e.g. nitrosoguanidine, ethyleneimine, etc.). Even such mutants can also be employed for the purposes of this invention only if they are still able to transform the maytansinoid compound (II) into C-15003 PND (I).
  • artifical means such as X-ray, UV, gamma-ray or other irradiation, or with a mutagenic agent (e.g. nitrosoguanidine, ethyleneimine, etc.).
  • a mutagenic agent e.g. nitrosoguanidine, ethyleneimine, etc.
  • the medium used for the cultivation of said microorganism in the method according to this invention may be a liquid medium or a solid medium, if it contains sources of nutrients which said microorganism can utilize, although a liquid medium is preferred for high production runs.
  • the carbon sources which said organism can assimilate the nitrogen sources which it can digest, inorganic substances, trace nutrients and so forth in suitable proportions.
  • the carbon sources may include, among others, glucose, lactose, sucrose, maltose, dextrin, starch, glycerol, mannitol, sorbitol, etc., oils and fats (e.g. soybean oil, lard oil, chicken oil, etc.), etc.
  • the nitrogen sources may include, among others, meat extract, yeast extract, dried yeast, soybean flour, corn steep liquor, peptone, cotton-seed flour, spent molasses, urea, ammonium salts (e.g. ammonium sulfate, ammonium chloride, ammonium nitrate, ammonium acetate, etc.) and the like.
  • ammonium salts e.g. ammonium sulfate, ammonium chloride, ammonium nitrate, ammonium acetate, etc.
  • use may also be made of salts of sodium, potassium, calcium, magnesium, etc., metal salts such as salts of iron, manganese, zinc, cobalt, nickel, etc.; salts of phosphoric acid, boric acid, etc; and salts of organic acids, such as salts of acetic acid, propionic acid, etc. It is further possible to incorporate amino acids (e.g.
  • inorganic or organic acids, alkalis, buffers, etc. for the purpose of adjusting the pH of medium or to add a suitable amount of oils, surfactants, etc. for defoaming purposes.
  • the cultivation method may be stationary culture, shake culture or aerated stirring culture. For high production runs, the so-called submerged aerobic culture is of course desirable. While cultivation conditions depend upon the condition and composition of medium, the particular strain or organism, cultural method employed and so forth, generally the cultivation is desirably carried out at a temperature in the range of 20°C to 45°C and at an initial pH level of near neutral. It is especially desirable to maintain the temperature at 24°C to 37°C at an intermediate phase of cultivation and start the cultivation at pH 6.5 to 8.5.
  • the cultivation time may range from 6 to 100 hours and the range of 16 to 48 hours is particularly desirable.
  • the term 'culture broth' as used in this specification means the broth obtained by the above- described cultivation procedure.
  • the term 'processed matter' means the mycelial or cellular products obtained from said culture broth by a physical or/and chemical treatments, e.g. filtration, centrifugation, super-sonication, French-press process, ginding with alumina, treatment with bacteriolytic enzymes, treatment with a surfactant or organic solvent, etc., or an equivalent milled product containing a demethylating enzyme. It is also possible to employ the corresponding demethylating enzyme obtained by a conventional purification procedure or such demethylating enzyme as immobilized by a conventional procedure.
  • the method of this invention is carried into practice by contacting the starting compound (II) with the culture broth or processed matter as obtained or derived from the above-mentioned microorganism.
  • concentration of said starting compound in the reaction system is preferably in the range of 100 to 500 ,ug/ml.
  • the reaction temperature and pH are desirably 20 to 50°C and pH 5 to 10, and more desirably about 24 to 40°C and pH 6 to 9.
  • the reaction time is 1 to 100 hours and, more desirably 24 to 72 hours.
  • the reaction may be conducted under stationary, shake, aerated or stirring conditions, although shake, aerated or stirring conditions are preferred.
  • the PND obtainable in the above manner can be detected by thin-layer chromatography (TLC hereinafter).
  • TLC thin-layer chromatography
  • the reaction mixture is extracted with ethyl acetate, concentrated to 1/100 by volume and subjected to TLC on a silica gel glass plate (Merck, Germany, Kieselgel 60F 254 , 0.25 mm, 20 x 20 cm) with H 2 0-saturated ethyl acetate, detection being made with ultraviolet light at 2537A.
  • the desired compound can be isolated from the reaction system by means of the isolation and purification procedures normally applied to the recovery of microbial metabolities.
  • Such procedures are exemplified by procedures utilizing differences in solubility with respect to impurities, procedures utilizing differences in adsorptive affinity for various adsorbents such as activated carbon, macroporous nonionic resin, silica gel, alumina, etc., and procedures for removing impurities with ion exchange resins, and these procedures may be used either independently, in combination or in repetition.
  • the suitable solvent for use in procedures utilizing a solubility difference include, for example, water-immiscible organic solvents such as fatty acid esters (e.g.
  • the extraction is carried out near neutral pH and a preferred procedure comprises adjusting the broth filtrate to pH 7 and extracting it with ethyl acetate.
  • the extract is then washed with water and concentrated under reduced pressure, and a nonpolar solvent such as petroleum ether or hexane is added.
  • a nonpolar solvent such as petroleum ether or hexane is added.
  • the crude product (i) containing the activity is thus obtained. Since the TLC of this crude product gives many spots other than the desired product compound PND, the following stepwise purification process is applied.
  • adsorption chromatographic techniques can be successfully utilized. While the adsorbents may be those commonly employed, e.g. silica gel, alumina, macroporous nonionic adsorbent resin, etc., silica gel is most effective for purification from crude product (i).
  • the adsorbent column is developed first with, for example, a nonpolar solvent such as petroleum ether or/and hexanei and, then, with the addition of a polar solvent or solvent system such as ethyl acetate, acetone, ethanol or/and methanol, whereby the desired compound PND is eluted.
  • a nonpolar solvent such as petroleum ether or/and hexanei
  • a polar solvent or solvent system such as ethyl acetate, acetone, ethanol or/and methanol
  • first and second silica gel columns may be reversed or identical. It is also possible to use other common organic solvents in various combinations.
  • PND is eluted with a mixture of water with a lower alcohol, lower ketone or ester.
  • the lower alcohol is exemplified by methanol, ethanol, propanol, butanol, etc., the lower ketone by acetone, methyl ethyl ketone, etc., and the ester by ethyl acetate, etc.
  • the crude product (ii) is dissolved in 50 V/V% aqueous methanol, the solution is passed through a column of Diaion HP-10 (Mitsubishi Chemical Industries, Ltd., Japan, the column is washed with 60 V/V% aqueous methanol, and the desired product PND is eluted with 90 V/V% aqueous methanol.
  • Diaion HP-10 Mitsubishi Chemical Industries, Ltd., Japan
  • the fraction is concentrated under reduced pressure and treated with petroleum ether to obtain powdery product.
  • PND can be used also as intermediate materials for the synthesis of pharmaceutically useful compounds.
  • a PND the compound (III)
  • the novel compound PND-0 having a hydroxyl group in 3-position.
  • the conventional reductive hydrolysis reaction can be employed with advantage.
  • a metal hydride complex compound e.g. lithium aluminium hydride (LiAIH 4 )] at a low temperature (e.g. -20 to 0°C)
  • the O-ester bond in 3-position can be hydrolyzed without affecting other functional groups, e.g. the carbonyl, epoxy, carbon-carbon double bond, etc., so as to yield a compound PND-0.
  • the isolation and purification of PND-0 can be performed in the same manner as described hereinbefore.
  • PND compound (111)
  • PND compound (111)
  • PND-0 can be transformed into PND-0 by contacting the former with a culture broth, inclusive of any processed matter derived therefrom, of a Streptomyces strain.
  • the microorganism to be employed in the practice of this invention may be an organism, inclusive of mutants thereof, which belongs to the genus Streptomyces and which is able to transform the 3- acyloxy group of compound (III) into a hydroxyl group.
  • Streptomyces coelicolor ATCC 13405 IFO-3807
  • the above ATCC 13405 strain is listed on The American Type Culture Collection Catalogue of Strains I (Thirteenth Edition 1978) and is available from ATCC.
  • the strain can also be obtained from Institute for Fermentation, Osaka as the IFO 3807 strain.
  • organisms of the genera Streptomyces are highly variable in characteristics and can be mutated by artificial means such as X-ray, UV, or other irradiation, or with a mutagenic agent (e.g. nitrosoguanidine, ethyleneimine, etc.). Even such mutants can also be employed for the purposes of this invention only if they are still able to transform the 3-acyloxy group of compound (III) into a hydroxyl group.
  • a mutagenic agent e.g. nitrosoguanidine, ethyleneimine, etc.
  • the medium used for the cultivation of said microorganism in the method according to this invention may be a liquid medium or a solid medium if it contains sources of nutrients which said microorganism can utilize, although a liquid medium is preferred for high production runs.
  • the carbon sources may include, among others, glucose, lactose, sucrose, maltose, dextrin, starch, glycerol, mannitol, sorbitol, etc., oils and fats (e.g. soybean oil, lard oil, chicken oil, etc.), etc.
  • the nitrogen sources may include, among others, meat extract, yeast extract, dried yeast, soybean flour, corn steep liquor, peptone, cotton-seed flour, spent molases, urea, ammonium salts (e.g. ammonium sulfate, ammonium chloride, ammonium nitrate, ammonium acetate, etc.) and the like.
  • ammonium salts e.g. ammonium sulfate, ammonium chloride, ammonium nitrate, ammonium acetate, etc.
  • use may also be made of salts of sodium, potassium, calcium, magnesium, etc., metal salts such as salts of iron, manganese, zinc, cobalt, nickel, etc.; salts of phosphoric acid, boric acid, etc., and salts of organic acids such as salts of acetic acid, propionic acid, etc. It is further possible to incorporate amino acids (e.g.
  • inorganic or organic acids, alkalis, buffers, etc. for the purpose of adjusting the pH of medium or to add a suitable amount of oils, surfactants, etc. for defoaming purposes.
  • the cultivation method may be stationary culture, shake culture or aerated stirring culture. For high production runs, the so-called submerged aerobic culture is of course desirable. While cultivation conditions depend upon the condition and composition of medium, the particular strain of organism, cultural method employed and so forth, generally the cultivation is desirably carried out at a temperature in the range of 20°C to 45°C and at an initial pH level of near neutral. It is especially desirable to maintain the temperature at 24°C to 37°C at an intermediate phase of cultivation and start the cultivation at a pH of 6.5 to 8.5.
  • the cultivation time may range from 6 to 100 hours and the range of 16 to 60 hours is particularly desirable.
  • the term 'culture broth' as used in this specification means the broth obtained by the above- described cultivation procedure.
  • the term 'processed matter' means the mycelial or cellular products obtained from said culture broth by a physical or/and chemical treatments, e.g. filtration, centrifugal separation, sonication, French-press process, grinding with alumina, treatment with bacteriolytic enzymes, treatment with a surfactant or organic solvent, etc., or an equivalent milled product containing a deacylating enzyme. It is also possible to employ the corresponding deacylating enzyme obtained by a conventional purification procedure or the cells or deacylating enzyme as immobilized by a conventional procedure.
  • the method of this invention is carried into practice by contacting the starting compound (II) with the culture broth or processed matter as obtained or derived from the above-mentioned microorganism.
  • concentration of said starting compound in the reaction system is preferably in the range of 1 to 200 ⁇ g/mI.
  • the reaction temperature and pH are desirably 20 to 50°C and pH 5 to 10, and more desirably about 24 to 40°C and pH 6 to 9.
  • the reaction time is 10 minutes to 100 hours and, more desirably 1 to 48 hours.
  • the reaction may be conducted under stationary, shake, aerated or stirring conditions, although shake, aerated or stirring conditions are preferred.
  • the product obtainable in the above manner can be detected by thin-layer chromatography (TLC hereinafter).
  • TLC thin-layer chromatography
  • the reaction mixture is extracted with ethyl acetate, concentrated to 1/100 by volume and subjected to TLC on a silica gel glass plate (Kieselgel 60F 254 , 0.25 mm, 20 x 20 cm) with a solvent system of chloroform and methanol (9:1 detection being made with ultraviolet light at 2537A.
  • P-0 maytansinol
  • P-1, P-2, P-3, P-3' and P-4 is identical with maytansinol which is the nucleus of maytansine [Nature 270, 721-722 (1977), Tetrahedron 35, 1079-1085 (1979)]
  • P-0, P-1 and P-2 respectively correspond to maytansinol, maytanacine and maytansinol propionate which are described in Journal of the American Chemical Society 97, 5294 (1975).
  • PND-4, PND-2, PND-1 and PND-0 are assumed to have the structures shown in Fig. 1.
  • trypticase-soy-agar (Baltimore Biologicals, U.S.A.) as a test medium
  • the minimal inhibitory concentration of each compound against the following microorganisms was determined by the paper disk method.
  • growth inhibition was investigated using paper disks (Toyo Roshi Corp., Japan thin-type, diam. 8 mm) imbibed with 0.02 ml of a 300 ⁇ g/ml solution of PND-1, PND-2, PND-3 or PND-4. The study showed that these compounds did not exhibit activity against the following microorganisms.
  • Escherichia coli Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis, Bacillus cereus, Klebsiella pneumoniae, Serratia marcescense, Mycobacterium avium.
  • a microbiological assay was carried out by the paper disk method using Hamigera avellanea IFO 7721 as a test organism. On said plate medium inoculated with said organism, growth inhibition was examined using a paper disk (Toyo Roshi Corp., Japan, Thin type, diam.
  • Tetrahymena pyriformis W strain as a test organism, was cultivated on an assay medium [Proteose-peptone (Difco) 20 g, yeast extract 1 g, glucose 2 g, distilled water 1000 ml, 1 M phosphate buffer (pH 7.0) 10 ml] at 28°C for 44 to 48 hours and the minimal inhibitory concentrations of the antibiotics against said organisms were determined by the serial broth dilution method. It was thus found that PND-1 inhibits growth of the above organism at the concentration of 8 ⁇ g/ml, PND-2 at the concentration of 4 ⁇ g/ml, PND-3 at 2 ⁇ g/ml and PND--4 at 1 pg/ml.
  • an assay medium [Proteose-peptone (Difco) 20 g, yeast extract 1 g, glucose 2 g, distilled water 1000 ml, 1 M phosphate buffer (pH 7.0) 10 ml] at 28°C for 44
  • PND-1, PND-2, PND-3 and PND-4 against P388 tumor cell (1 x 10 6 cell/mouse, intraperitoneal) was investigated. The results indicate that these compounds prolong the life span of a tumor-bearing mouse.
  • mice In an acute toxicity test performed in mice, PND-1, PND-2, PND-3 and PND-4 were given to animals by the intraperitoneal route.
  • the LD 100 and LD O of all these compounds were invariably 2.5 mg/kg and 0.313 mg/kg, respectively.
  • PND have strong inhibitory actions against fungi and protozoa and are therefore valuable as antifungal or/and antiprotozoal agents. Moreover, PND are also considered to be useful as an antitumor agent in view of their action to increase the survival time of a tumor-bearing mammal (e.g. mouse).
  • a tumor-bearing mammal e.g. mouse
  • the compounds can be advantageously used as a testing agent for the assay of bacterial ecology in a soil, activated sludge, animal fluid or other sample.
  • the above compounds can be utilized to permit selective growth of bacterial life without allowing concomitant protozoa in the specimen to grow.
  • An exemplary specific procedure comprises adding the specimen to a liquid or solid medium, then adding 0.1 ml of a 1 % aqueous solution of methanol containing 10 to 100 ,ug/ml of this compound to each ml of the medium and incubating the mixture.
  • PND prolongs the survival times of warm-blooded animals (e.g. mouse, rat, dog, cat, etc.), these compounds can be used as antitumor drugs.
  • PND can be administered orally or otherwise.
  • routes other than oral injection is preferred.
  • PND may be administered subcutaneously, intraperitoneally, intravenously or intramuscularly, for instance.
  • the dosage may range from about 5 to 800 ⁇ g/kg body weight/one dose, for instance, and be varied with reference to condition, animal species, etc.
  • Such an injection can be prepared in the conventional manner.
  • about 50 ,ug to 3000 ⁇ g of the compound (I) of this invention is dissolved in about 0.5 ml of alcohol (e.g. methanol, ethanol), followed by addition of physiological saline to make a total of 10 ml.
  • alcohol e.g. methanol, ethanol
  • PND-0 can be useful as a synthetic intermediate for the production of useful drugs.
  • the compound of general formula (I) wherein R is a substituent group other than hydrogen can be produced by reacting PND-0 with the corresponding carboxylic anhydride in the presence of a base.
  • the base may for example be a tertiary amine such as triethylamine, pyridine, 4-dimethylaminopyridine or the like.
  • Streptomyces minutisceleroticus IFO 13361 was inoculated into a medium (pH 7.2) containing 1% dextrin, 1% glucose, 1% glycerol, 0.5% peptone, 0.5% yeast extract, 0.5% meat extract, 0.3% sodium chloride and 0.5% precipitated calcium carbonate, and cultivation was carried out under shaking at 28°C for 22 hours. To 5 I of the resulting culture was added 1 g of P-3 and the reaction was carried out under shaking for 72 hours to obtain a reaction mixture. Thin-layer chromatography (TLC) of this reaction mixture showed that P-3 had decreased in amount and, instead, PND-3 had been produced.
  • TLC Thin-layer chromatography
  • Example 2 To 5 I of the reaction mixture obtained in Example 1 was added 2.5 I of ethyl acetate, and extraction was carried out under stirring. The extract was suction-filtered through a Buchner's funnel precoated with 60 g of Hyflo Super Cel (Johnes Manville Sales Corp. U.S.A.). The above procedure was repeated twice. The ethyl acetate layers were combined and washed with 1.5 I of 1/200 N hydrochloric acid, twice with one liter of 1/10 M aqueous sodium carbonate and twice with one liter of water.
  • Example 3 The reaction mixture obtained in Example 3 was subjected to purification as Example 2 and subjected to TLC with the same developing solvent H 2 0-saturated ethyl acetate as used in Example 2. The fractions around R f 0.55 were collected to recover a white powder of PND-4 (28 mg).
  • Example 6 The reaction mixture obtained in Example 6 was subjected to purification as Example 2 and subjected to TLC with the same developing solvent H 2 0-saturated ethyl acetate as used in Example 2. The fractions around R f 0.37 were collected to recover crystals PND-1 (34 mg).
  • Example 8 The reaction mixture obtained in Example 8 was subjected to purification as Example 2 and subjected to TLC with the same developing solvent H 2 0-saturated ethyl acetate as used in Example 2. The fractions around R f 0.42 were collected to recover PND-2 crystals (26 mg).
  • Example 12 The reaction mixture obtained in Example 12 was purified in the same manner as Example 2 and subjected to TLC with the same developing solvent chloroform-methanol (9:1) used in Example 2. The fractions around R f 0.30 were collected to recover crystals of PND-0 (72 mg).
  • PND-3 50 mg was added to 1 I of a culture broth of Streptomyces coelicolor ATCC 13405 (IFO 3807) as obtained by cultivation in the same manner as Example 1 and the reaction was carried out under shaking at 28°C for 2 days to obtain a reaction mixture. TLC assay of this reaction mixture showed that the amount of PND-3 had disappeared and, instead, PND-0 formed in the mixture.
  • Example 17 The reaction mixture obtained in Example 17 was extracted with an equal volume of ethyl acetate and the extract was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to recover 73 mg of residue. This residue was dissolved in 0.5 ml of chloroform and the solution subjected to preparative thin-layer chromatography using 12 silica gel glass plates (Kieselgel 60 F254). After development with H 2 0-saturated ethyl acetate, the silica gel absorbing in the neighborhood of R f 0.25 is scraped off and extracted with ethyl acetate containing a small amount of water. The extract was washed with water, dried, concentrated under reduced pressure and allowed to stand. The above procedure provided crystals of PND-0 (24 mg). The physicochemical properties of these crystals were in agreement with those of PND-0 samples obtained in Examples 13 or 16.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP80105162A 1979-09-21 1980-08-29 Antibiotic c-15003 pnd-0 and production of antibiotic c-15003 pnd Expired EP0025898B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT80105162T ATE3059T1 (de) 1979-09-21 1980-08-29 Antibiotikum c-15003 pnd-0 und herstellung von antibiotikum c-15003 pnd.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12221779A JPS5645485A (en) 1979-09-21 1979-09-21 Production of c-15003pnd
JP122217/79 1979-09-21

Publications (3)

Publication Number Publication Date
EP0025898A2 EP0025898A2 (en) 1981-04-01
EP0025898A3 EP0025898A3 (en) 1981-10-14
EP0025898B1 true EP0025898B1 (en) 1983-04-13

Family

ID=14830442

Family Applications (1)

Application Number Title Priority Date Filing Date
EP80105162A Expired EP0025898B1 (en) 1979-09-21 1980-08-29 Antibiotic c-15003 pnd-0 and production of antibiotic c-15003 pnd

Country Status (6)

Country Link
US (1) US4362663A (cs)
EP (1) EP0025898B1 (cs)
JP (1) JPS5645485A (cs)
AT (1) ATE3059T1 (cs)
CA (1) CA1142467A (cs)
DE (1) DE3062752D1 (cs)

Families Citing this family (430)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3440735A1 (de) * 1984-11-08 1986-05-15 Hoechst Ag, 6230 Frankfurt Bakterienlysierendes enzymprodukt aus streptomyceten, verfahren zu seiner herstellung und dafuer geeigneter stamm
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
KR20020012292A (ko) 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100607612B1 (ko) 2001-06-20 2006-08-02 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
KR100801388B1 (ko) 2002-01-02 2008-02-05 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ATE516047T1 (de) 2003-05-09 2011-07-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und anwendungsverfahren
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3031810B1 (en) 2003-05-20 2019-03-06 ImmunoGen, Inc. Maytansinoid-cell-binding agent conjugates
HUE045709T2 (hu) 2003-07-08 2020-01-28 Genentech Inc Antagonista antitestek IL-17A/F heterológ polipeptidekhez
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
EP2161283B1 (en) 2003-11-17 2014-06-04 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
JP5234734B2 (ja) * 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド 抗体−薬物結合体および方法
US7740846B2 (en) 2004-07-20 2010-06-22 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX2007001064A (es) 2004-07-26 2007-04-12 Genentech Inc Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AU2005279720B2 (en) * 2004-09-03 2011-07-28 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2230517A1 (en) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110 antibody compositions and methods of use
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
CA2597407C (en) 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CN101267841B (zh) * 2005-08-24 2012-10-10 免疫原公司 制备美登木素生物碱抗体缀合物的方法
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
CN105859886A (zh) 2005-12-02 2016-08-17 健泰科生物技术公司 牵涉与il-22和il-22r结合的抗体的组合物和方法
AU2006338198B2 (en) * 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
CN103396485B (zh) 2005-12-15 2016-08-10 健泰科生物技术公司 靶向多聚泛蛋白的方法和组合物
BRPI0706840A2 (pt) 2006-01-05 2011-04-05 Genentech Inc anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
KR101459160B1 (ko) 2006-01-20 2014-11-19 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
AU2007266521C1 (en) 2006-05-30 2012-12-20 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8460667B2 (en) 2006-07-18 2013-06-11 Sanofi EPHA2 receptor antagonist antibodies
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2061814T3 (pl) 2006-10-27 2012-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ES2543350T3 (es) 2006-11-27 2015-08-18 Diadexus, Inc. Composiciones de anticuerpos de Ovr110 y métodos de uso
JP5276017B2 (ja) 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ変異体仲介性疾患の治療における抗ｅｇｆｒ抗体の使用
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9845355B2 (en) 2007-07-16 2017-12-19 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
DK2176296T3 (da) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
CN101842115B (zh) 2007-08-29 2014-07-30 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
US8057796B2 (en) 2007-11-12 2011-11-15 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
RU2486203C2 (ru) * 2007-12-26 2013-06-27 Биотест Аг Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
KR101654822B1 (ko) * 2007-12-26 2016-09-06 바이오테스트 아게 Ｃｄ138 표적성 면역접합체 및 이의 용도
WO2009080829A1 (en) 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
JP2011507933A (ja) * 2007-12-26 2011-03-10 バイオテスト・アクチエンゲゼルシヤフト 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
PE20140853A1 (es) 2008-01-31 2014-08-04 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
AU2009223688B2 (en) 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
CN104873980B (zh) 2008-03-18 2019-07-19 健泰科生物技术公司 抗her2抗体-药物偶联物和化疗剂的组合，及使用方法
KR101855381B1 (ko) 2008-04-09 2018-05-09 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
CN102076717B (zh) 2008-04-30 2016-02-03 伊缪诺金公司 交联剂和它们的用途
KR101511453B1 (ko) * 2008-05-16 2015-04-10 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
ES2541726T3 (es) 2008-10-01 2015-07-23 F. Hoffmann-La Roche Ag Anticuerpos anti-Notch2 y métodos de uso
BRPI0923034A2 (pt) 2008-12-17 2015-12-15 Genentech Inc terapia de combinação para virus da hepatite c
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
KR101830024B1 (ko) 2009-03-25 2018-02-19 제넨테크, 인크. 항-ｆｇｆｒ３ 항체 및 그의 사용 방법
AR076029A1 (es) 2009-04-01 2011-05-11 Genentech Inc Anticuerpos anti- fcrh5 (receptor de translocacion asociado a la superfamilia de inmunoglobulina) e inmunoconjugados y metodos de uso
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2010126979A1 (en) 2009-04-29 2010-11-04 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012526839A (ja) 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
SI2437790T1 (sl) 2009-06-03 2019-07-31 Immunogen, Inc. Konjugacijske metode
CN102458479B (zh) 2009-06-04 2016-07-13 诺华公司 识别IgG结合位点的方法
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
BR112012009245A2 (pt) * 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
CN102648211B (zh) 2009-10-22 2015-04-01 霍夫曼-拉罗奇有限公司 抗hepsin抗体及其使用方法
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011057120A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
AR078377A1 (es) 2009-12-11 2011-11-02 Genentech Inc Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
HUE030854T2 (en) 2010-02-24 2017-06-28 Immunogen Inc Immunoconjugates against folate receptor 1 and their use
RS59389B1 (sr) 2010-03-12 2019-11-29 Debiopharm Int Sa Cd37-vezujući molekuli i njihovi imunokonjugati
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
PH12012501963A1 (en) 2010-05-03 2013-01-07 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
CN119552249A (zh) 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
CN103052649B (zh) 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
AU2011289275A1 (en) 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
CA2809837C (en) 2010-08-31 2019-12-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
JP6083871B2 (ja) 2010-09-29 2017-02-22 アジェンシス，インコーポレイテッド １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
JP5974012B2 (ja) 2010-10-05 2016-08-23 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
KR20140008308A (ko) 2010-10-29 2014-01-21 이뮤노젠 아이엔씨 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트
EP2632947A4 (en) 2010-10-29 2015-03-18 Immunogen Inc NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP6161540B2 (ja) 2011-02-04 2017-07-12 ジェネンテック， インコーポレイテッド Ｆｃ変異体及びそれらの生産方法
JP2014506580A (ja) 2011-02-14 2014-03-17 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
RU2013144392A (ru) 2011-03-03 2015-04-10 Апексиджен, Инк. Антитела к рецептору il-6 и способы применения
BR112013023576A2 (pt) 2011-03-15 2016-12-06 Theraclone Sciences Inc composições e métodos para a terapia e diagnóstico de influenza
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
PT2691155T (pt) 2011-03-29 2019-02-19 Immunogen Inc Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapa
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
MX2013013104A (es) 2011-05-09 2014-10-15 Univ Virginia Patent Found Composiciones y metodos para el tratamiento de cancer.
CN106279418A (zh) 2011-05-27 2017-01-04 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白
CA2837840C (en) 2011-06-10 2020-08-04 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
BR112013032928A2 (pt) 2011-06-21 2017-01-24 Immunogen Inc "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
JP2014525412A (ja) 2011-08-17 2014-09-29 ジェネンテック， インコーポレイテッド 難治性腫瘍における血管新生の阻害
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2776051A4 (en) 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
RU2014122184A (ru) 2011-11-02 2015-12-10 Апексиджен, Инк. Антитела к kdr и способы их применения
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
CA2858133A1 (en) 2011-12-08 2013-06-13 Biotest Ag Uses of immunoconjugates targeting cd138
EP2793940B1 (en) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
WO2013109994A1 (en) 2012-01-20 2013-07-25 Sea Lane Biotechnologies, Llc Surrobody cojugates
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013165940A1 (en) 2012-05-01 2013-11-07 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
CN102731526B (zh) * 2012-05-14 2014-09-10 福建省微生物研究所 安丝菌素类化合物及其制备方法
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CN110256567B (zh) 2012-06-27 2023-04-25 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
DK2887959T3 (en) 2012-08-23 2019-02-18 Agensys Inc ANTIBODY-PHARMACEUTICAL CONJUGATES (ADC) BINDING TO 158P1D7 PROTEINS
HK1213288A1 (zh) 2012-10-04 2016-06-30 Immunogen, Inc. 使用pvdf膜純化細胞結合劑細胞毒性劑綴合物
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
NZ708528A (en) 2012-11-20 2020-07-31 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EA201591219A1 (ru) 2012-12-27 2015-12-30 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US9498543B2 (en) 2013-03-15 2016-11-22 Novartis Ag Antibody drug conjugates
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
EP3456743B1 (en) 2013-05-30 2021-08-18 Kiniksa Pharmaceuticals, Ltd. Oncostatin m receptor antigen binding proteins
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EP3022221B1 (en) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
PL3027208T3 (pl) 2013-07-31 2020-11-02 BioNTech SE Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
KR20160060634A (ko) 2013-08-01 2016-05-30 어젠시스 인코포레이티드 Ｃｄ37 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
HK1218124A1 (zh) 2013-09-17 2017-02-03 豪夫迈．罗氏有限公司 使用抗lgr5抗体的方法
JP6463744B2 (ja) 2013-10-08 2019-02-06 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
SG11201602460QA (en) 2013-10-11 2016-04-28 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
MX377297B (es) 2013-10-11 2025-03-07 Us Health Anticuerpos tem8 y su uso.
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
PL3054992T3 (pl) 2013-10-11 2020-01-31 Asana Biosciences, Llc Koniugaty białko-polimer-lek
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
CN105814084B (zh) 2013-12-13 2019-09-24 基因泰克公司 抗cd33抗体和免疫缀合物
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
RU2016130349A (ru) 2014-01-24 2018-03-01 Дженентек, Инк. Способы применения антител против steap1 и иммуноконъюгатов
EP3102197B1 (en) 2014-02-04 2018-08-29 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
RU2016150370A (ru) 2014-05-22 2018-06-26 Дженентек, Инк. Антитела и иммуноконъюгаты против GPC3
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
IL249188B2 (en) 2014-05-27 2024-03-01 Academia Sinica Anti-her2 glycoantibodies and uses thereof
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015302959B2 (en) 2014-08-12 2018-09-20 Novartis Ag Anti-CDH6 antibody drug conjugates
KR102615681B1 (ko) 2014-08-28 2023-12-18 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
JP2017526682A (ja) 2014-09-02 2017-09-14 イミュノジェン， インコーポレイテッド 抗体薬物複合体組成物の製剤化方法
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
WO2016049214A1 (en) 2014-09-23 2016-03-31 Genentech, Inc. METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
EP3200829B1 (en) 2014-10-01 2023-12-06 Medimmune, LLC Method of conjugating a polypeptide
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
AU2015349985A1 (en) 2014-11-19 2017-05-25 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10889653B2 (en) 2014-11-26 2021-01-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
ES2986970T3 (es) 2014-12-04 2024-11-13 Celgene Corp Conjugados de biomoléculas
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
KR102630294B1 (ko) 2015-01-24 2024-01-26 아카데미아 시니카 암 마커 및 이를 사용하는 방법
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN107614010A (zh) 2015-03-09 2018-01-19 艾更斯司股份有限公司 结合至flt3蛋白的抗体药物偶联物(adc)
EP3271401A4 (en) 2015-03-18 2018-11-21 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
KR20240093813A (ko) 2015-04-24 2024-06-24 제넨테크, 인크. 다중특이적 항원-결합 단백질
EP4286511A3 (en) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. BRIDGE LINKER FOR CONJUGATING CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
CA2996205A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
EP3660044A1 (en) 2015-10-09 2020-06-03 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
AU2017213858A1 (en) 2016-02-05 2018-08-16 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017180713A1 (en) 2016-04-13 2017-10-19 Orimabs Ltd. Anti-psma antibodies and use thereof
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
LT3455261T (lt) 2016-05-13 2022-11-10 Bioatla, Inc. Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
AU2017305170A1 (en) 2016-08-02 2019-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
KR102459469B1 (ko) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN110023334B (zh) 2016-11-21 2023-11-14 科雅博有限责任公司 抗gp73抗体和免疫偶联物
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
EP3565830B1 (en) 2017-01-09 2021-03-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
AU2018240556B2 (en) 2017-03-24 2025-02-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
CA3059472A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
JP7320458B2 (ja) 2017-06-22 2023-08-03 メルサナ セラピューティクス インコーポレイテッド 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
AU2018309735B2 (en) 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
JP7334147B2 (ja) 2017-08-22 2023-08-28 パーデュー・リサーチ・ファウンデイション 炭酸脱水酵素陽性がんを標的とするｆｂｓａ系治療および放射性造影複合体
WO2019055842A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD19 IMMUNOTHERAPY
CA3078962A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
JP2021500391A (ja) 2017-10-24 2021-01-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｄ１１７＋細胞を減少させるための組成物及び方法
WO2019090110A1 (en) 2017-11-03 2019-05-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ror1 immunotherapy
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
EP3728307A4 (en) 2017-12-20 2021-05-19 Lentigen Technology, Inc. Compositions and methods for treating hiv/aids with immunotherapy
WO2019183438A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3099421C (en) 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B V COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
AU2019262520B2 (en) 2018-05-04 2025-07-10 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
AU2019299357A1 (en) 2018-07-02 2021-01-14 Amgen Inc. Anti-steap1 antigen-binding protein
AU2019301675B2 (en) 2018-07-12 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
WO2020023561A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
CN118291501A (zh) 2018-09-20 2024-07-05 莱蒂恩技术公司 用于用抗cd123免疫治疗来治疗癌症的组合物和方法
AU2019350865A1 (en) 2018-09-26 2021-04-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
CN119592592A (zh) 2018-11-30 2025-03-11 莱蒂恩技术公司 用于用抗cd38免疫治疗来治疗癌症的组合物和方法
BR112021010908A2 (pt) 2018-12-06 2021-08-31 Genentech, Inc. Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
US12180296B2 (en) 2019-01-08 2024-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
EP3883971A1 (en) 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
KR20210124260A (ko) 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
ES2949511T3 (es) 2019-03-01 2023-09-29 Celgene Corp Preparación de maitansinol
CA3132660A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
WO2020243546A1 (en) 2019-05-30 2020-12-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-bcma immunotherapy
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
EP4382129A3 (en) 2019-06-17 2024-07-03 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用
CN114945386A (zh) 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
CA3156761A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
AU2020402752A1 (en) 2019-12-12 2022-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for CD276 and uses thereof
MX2022013406A (es) 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
KR20230005903A (ko) 2020-04-24 2023-01-10 제넨테크, 인크. 항-CD79b 면역접합체를 사용하는 방법
AU2021261553A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFIFI
JP2023522396A (ja) 2020-04-24 2023-05-30 サノフイ 抗ｃｅａｃａｍ５抗体コンジュゲート、トリフルリジン、およびチピラシルを含有する抗腫瘍組み合わせ
KR20230005203A (ko) 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 folfox를 함유하는 항종양 조합
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN116829581A (zh) 2020-06-22 2023-09-29 莱蒂恩技术公司 用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3171093A1 (en) 2020-11-05 2022-05-12 Dina SCHNEIDER Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
CA3200974A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination therapy
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
EP4337266A1 (en) 2021-05-12 2024-03-20 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240099150A (ko) 2021-09-06 2024-06-28 베락사 바이오테크 게엠베하 진핵생물에서의 유전자 코드 확장을 위한 신규 아미노아실-tRNA 합성효소 변이체
CN118159294A (zh) 2021-10-05 2024-06-07 葛兰素史密斯克莱知识产权发展有限公司 用于治疗癌症的联合疗法
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
KR20240099412A (ko) 2021-11-05 2024-06-28 사노피 항-ceacam5 항체-약물 접합체 및 항-vegfr-2 항체를 함유하는 항종양 조합
JP2024540451A (ja) 2021-11-18 2024-10-31 オックスフォード バイオセラピューティックス リミテッド 組合せ医薬
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
US20250144255A1 (en) 2021-11-25 2025-05-08 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
DK4186529T3 (da) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
CA3241254A1 (en) 2021-12-02 2023-06-08 Sanofi Ceacam5 adc-anti-pd1/pd-l1 combination therapy
TW202339804A (zh) 2021-12-02 2023-10-16 法商賽諾菲公司 在癌症療法中用於患者選擇的ｃｅａ測定
JP2024546769A (ja) 2021-12-08 2024-12-26 ヨーロピアン モレキュラー バイオロジー ラボラトリー 標的複合体の調製のための親水性テトラジン機能化ペイロード
EP4314031B1 (en) 2022-02-15 2024-03-13 Tagworks Pharmaceuticals B.V. Masked il12 protein
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
CN119836306A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 与cdcp1结合的抗体药物缀合物和其用途
CN119923410A (zh) 2022-07-28 2025-05-02 莱蒂恩技术公司 用于治疗实体瘤的嵌合抗原受体治疗
CA3265857A1 (en) 2022-08-26 2024-02-29 Lentigen Tech Inc COMPOSITIONS AND METHODS OF CANCER TREATMENT BY ALL-HUMAN ANTI-CD20/CD19 IMMUNOTHERAPY
IL320221A (en) 2022-10-12 2025-06-01 Tagworks Pharmaceuticals B V Strained bicyclo-nonanes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
AU2024228735A1 (en) 2023-03-01 2025-10-16 Sanofi Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
WO2024191293A1 (en) 2023-03-10 2024-09-19 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
AU2024240376A1 (en) 2023-03-23 2025-11-06 Sanofi CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
TW202513094A (zh) 2023-06-05 2025-04-01 法商賽諾菲公司 含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
TW202504641A (zh) 2023-06-08 2025-02-01 美商建南德克公司 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025021929A1 (en) 2023-07-27 2025-01-30 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025169012A1 (en) 2024-02-06 2025-08-14 Sanofi Methods of treating ceacam5-expressing cancers
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151042A (en) * 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4162940A (en) * 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
GR63147B (en) * 1978-03-24 1979-09-24 Takeda Chemical Industries Ltd Preparation process of demethyl maytansinoids
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation

Also Published As

Publication number Publication date
EP0025898A3 (en) 1981-10-14
DE3062752D1 (en) 1983-05-19
JPS5645485A (en) 1981-04-25
EP0025898A2 (en) 1981-04-01
ATE3059T1 (de) 1983-04-15
JPH0115514B2 (cs) 1989-03-17
US4362663A (en) 1982-12-07
CA1142467A (en) 1983-03-08

Similar Documents

Publication Publication Date Title
EP0025898B1 (en) Antibiotic c-15003 pnd-0 and production of antibiotic c-15003 pnd
US4331598A (en) Maytansinoids
US4364866A (en) Maytansinoids
US4225494A (en) Maytansinol esters
US4322348A (en) Maytansinoids
US4151042A (en) Method for producing maytansinol and its derivatives
EP0031430B1 (en) A method for the production of antibiotic c-15003 p-3
US4421687A (en) Macbecin derivatives
US4228239A (en) Method for producing antibiotic C-15003 P-3
CA1054959A (en) Rifamycins from nocardia mediterranea
CA1092999A (en) Method for producing maytansinol and its derivatives
US4229533A (en) Method for producing antibiotic C-15003 P-4
US4764602A (en) Antibiotics, and their production
EP0043280A1 (en) Process for preparing a macrolide
EP0187049B1 (en) Micromonospora microorganisms and macrolide antibiotic production therewith
CA1107212A (en) Antibiotic c-15003
GB2042502A (en) Antibiotics c-14482 b1,b2 and b3
KR810001056B1 (ko) 항생물질 c-15003의 제조법
CA1121814A (en) Antibiotic c-15003
CA1265758A (en) Antibiotics, and their production
EP0195872A2 (en) Novel cell-cidal antibiotic 82-85-8A and its production
JPS6361951B2 (cs)
JPS6213959B2 (cs)
JPH0434555B2 (cs)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAKEDA CHEMICAL INDUSTRIES, LTD.

17P Request for examination filed

Effective date: 19820218

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19830413

Ref country code: NL

Effective date: 19830413

Ref country code: LI

Effective date: 19830413

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 19830413

Ref country code: FR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19830413

Ref country code: CH

Effective date: 19830413

Ref country code: BE

Effective date: 19830413

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830413

REF Corresponds to:

Ref document number: 3059

Country of ref document: AT

Date of ref document: 19830415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3062752

Country of ref document: DE

Date of ref document: 19830519

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830831

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
EN Fr: translation not filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840828

Year of fee payment: 5

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19870501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881118

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT